XTNT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Xtant Medical Holdings Inc (XTNT) is not a strong buy at this time for a beginner investor with a long-term strategy. The company's financial performance shows mixed results, with revenue growth but declining net income and EPS. Technical indicators are neutral to bearish, and there are no strong proprietary trading signals or significant trading trends to support an immediate buy decision. While the acquisition of Dilon's U.S. sales team and exclusive distribution rights for HEMOBLAST® Bellows is a positive catalyst, it is not enough to outweigh the current financial and technical weaknesses.
The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 41.714, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.483, with resistance at 0.518 and support at 0.447. Overall, the technical indicators suggest a neutral to bearish trend.
Xtant has acquired Dilon's U.S. sales team and secured exclusive distribution rights for HEMOBLAST® Bellows, which could enhance its market presence in the hemostatic products sector.
The company's net income and EPS have significantly declined in the latest quarter, and there are no significant hedge fund or insider trading trends to indicate strong confidence in the stock.
In Q4 2025, revenue increased by 2.68% YoY to $32,357,000. However, net income dropped by -101.80% YoY to $57,000, and EPS fell to 0, down -100.00% YoY. Gross margin improved to 54.87%, up 7.91% YoY.
No analyst rating or price target changes are available for XTNT.
